Seek Returns

AMGN vs. LLY: Amgen vs. Eli Lilly Stock Comparison

How do Amgen (AMGN) and Eli Lilly (LLY) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Amgen (AMGN) and Eli Lilly (LLY) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but AMGN is classified in Biotechnology while LLY is classified in Pharmaceuticals.

Company profile comparison for Amgen (AMGN) and Eli Lilly (LLY)
Profile ItemAMGNLLY
NameAmgen Inc.Eli Lilly and Company
Country/RegionUnited StatesUnited States
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnologyPharmaceuticals
GICS Sub-IndustryBiotechnologyPharmaceuticals
Market Capitalization236.38 billion USD1,024.93 billion USD
CurrencyUSDUSD
ExchangeNasdaqNYSE
Listing DateJune 17, 1983June 1, 1972
Security TypeCommon StockCommon Stock

Price Performance

Cumulative Growth

AMGN
LLY
GSPC
Loading price history…
Amgen (AMGN) vs. Eli Lilly (LLY), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for Amgen (AMGN) and Eli Lilly (LLY). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for Amgen (AMGN) and Eli Lilly (LLY). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Amgen (AMGN) and Eli Lilly (LLY)
MetricAMGNLLY
Total Return (1Y)60.43%55.69%
Total Return (3Y, Annualized)23.06%28.18%
Total Return (5Y, Annualized)17.68%35.89%

Risk Profile

Drawdown History

AMGN
LLY
GSPC
Loading price history…
Amgen (AMGN) vs. Eli Lilly (LLY), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for Amgen (AMGN) and Eli Lilly (LLY). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Amgen (AMGN) and Eli Lilly (LLY)
MetricAMGNLLY
Volatility (1Y, Annualized)27.61%35.83%
Beta (5Y)0.410.45
Max Drawdown (5Y)-24.86%-34.48%
Avg. Volume (3M)2.67M2.87M

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
AMGN and LLY are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Amgen (AMGN) and Eli Lilly (LLY)
MetricAMGNLLY
Sharpe Ratio (1Y)2.041.44
Sortino Ratio (1Y)3.642.46

Profitability

ROE (TTM)

Both Amgen (AMGN) at 91.47% and Eli Lilly (LLY) at 102.29% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.

AMGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

91.47%

Max
102.29%
AMGN
91.47%
Q3
3.16%
Median
-32.34%
Q1
-64.79%
Min
-157.61%

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

102.29%

LLY
102.29%
Max
102.29%
Q3
3.16%
Median
-32.34%
Q1
-64.79%
Min
-157.61%
Loading chart…
Amgen (AMGN) vs. Eli Lilly (LLY): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Both Amgen (AMGN) at 22.95% and Eli Lilly (LLY) at 33.53% keep an unusually large share of revenue as bottom-line profit — each net margin clears its industry’s benchmark range.

AMGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

22.95%

AMGN
22.95%
Max
12.02%
Q3
2.44%
Median
0.00%
Q1
-4.89%
Min
-13.51%

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

33.53%

LLY
33.53%
Max
12.02%
Q3
2.44%
Median
0.00%
Q1
-4.89%
Min
-13.51%
Loading chart…
Amgen (AMGN) vs. Eli Lilly (LLY): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Both Amgen (AMGN) at 35.55% and Eli Lilly (LLY) at 54.22% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

AMGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

35.55%

Max
76.04%
AMGN
35.55%
Q3
10.45%
Median
0.00%
Q1
-120.32%
Min
-308.66%

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

54.22%

Max
76.04%
LLY
54.22%
Q3
10.45%
Median
0.00%
Q1
-120.32%
Min
-308.66%
Loading chart…
Amgen (AMGN) vs. Eli Lilly (LLY): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Amgen (AMGN) and Eli Lilly (LLY)
MetricAMGNLLY
ROE (TTM)91.47%102.29%
ROA (TTM)8.67%20.36%
Net Margin (TTM)22.95%33.53%
Operating Margin (TTM)35.55%54.22%
Gross Margin (TTM)71.89%83.40%

Growth

Revenue Growth

Both Amgen (AMGN) at 9.95% and Eli Lilly (LLY) at 44.70% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Loading chart…
Amgen (AMGN) vs. Eli Lilly (LLY): A comparison of their Revenue Growth across different time periods.

EPS Growth

Both Amgen (AMGN) at 88.23% and Eli Lilly (LLY) at 95.99% sit in the top peer quartile for EPS growth, so each is compounding per-share earnings faster than typical industry peers.

Loading chart…
Amgen (AMGN) vs. Eli Lilly (LLY): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Amgen (AMGN) and Eli Lilly (LLY)
MetricAMGNLLY
Revenue Growth (YoY)9.95%44.70%
Revenue Growth (3Y CAGR)11.77%31.69%
EPS Growth (YoY)88.23%95.99%
EPS Growth (3Y CAGR)5.52%51.71%

Financial Strength

Current Ratio (MRQ)

Both Amgen (AMGN) at 1.37 and Eli Lilly (LLY) at 1.36 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

AMGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.37

Max
26.10
Q3
12.34
Median
5.72
Q1
2.80
AMGN
1.37
Min
0.10

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.36

Max
26.10
Q3
12.34
Median
5.72
Q1
2.80
LLY
1.36
Min
0.10
Loading chart…
Amgen (AMGN) vs. Eli Lilly (LLY): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Debt sits unusually high against shareholders’ equity for both Amgen (AMGN) at 4.90 and Eli Lilly (LLY) at 1.62 — each debt-to-equity ratio is above its industry benchmark range.

AMGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.90

AMGN
4.90
Max
1.56
Q3
0.64
Median
0.14
Q1
0.02
Min
0.00

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.62

LLY
1.62
Max
1.56
Q3
0.64
Median
0.14
Q1
0.02
Min
0.00
Loading chart…
Amgen (AMGN) vs. Eli Lilly (LLY): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Amgen (AMGN) and Eli Lilly (LLY)
MetricAMGNLLY
Current Ratio (MRQ)1.371.36
Debt / Equity (MRQ)4.901.62
Net Debt / EBITDA2.511.10

Dividends

Dividend Yield (TTM)

Both Amgen (AMGN) at 2.21% and Eli Lilly (LLY) at 0.56% yield above their industries’ entire benchmark ranges — high enough that dividend safety, not income, becomes the first question.

AMGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.21%

AMGN
2.21%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.56%

LLY
0.56%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Amgen (AMGN) vs. Eli Lilly (LLY): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Both Amgen (AMGN) at 60.87% and Eli Lilly (LLY) at 21.69% pay out more of their earnings than any of their industry peers — the thinnest cover in their groups, so dividend headroom deserves attention.

AMGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

60.87%

AMGN
60.87%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

21.69%

LLY
21.69%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Amgen (AMGN) vs. Eli Lilly (LLY): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Amgen (AMGN) and Eli Lilly (LLY)
MetricAMGNLLY
Dividend Yield (TTM)2.21%0.56%
Dividend Payout Ratio (TTM)60.87%21.69%

Valuation

P/E Ratio (TTM)

Both Amgen (AMGN) at 27.17 and Eli Lilly (LLY) at 38.61 land around their industries’ usual P/E ratio levels — neither is getting a clear earnings-multiple discount or premium versus peers.

AMGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

27.17

Max
83.73
Q3
44.68
Median
28.50
AMGN
27.17
Q1
15.51
Min
0.14

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

38.61

Max
83.73
Q3
44.68
LLY
38.61
Median
28.50
Q1
15.51
Min
0.14
Loading chart…
Amgen (AMGN) vs. Eli Lilly (LLY): A comparison of their P/E ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/S Ratio (TTM)

On P/S ratio, both Amgen (AMGN) at 6.21 and Eli Lilly (LLY) at 12.86 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

AMGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.21

Max
65.27
Q3
29.50
Median
7.31
AMGN
6.21
Q1
3.49
Min
0.01

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

12.86

Max
65.27
Q3
29.50
LLY
12.86
Median
7.31
Q1
3.49
Min
0.01
Loading chart…
Amgen (AMGN) vs. Eli Lilly (LLY): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Measured against book value, both Amgen (AMGN) at 20.22 and Eli Lilly (LLY) at 30.24 look expensive — each P/B ratio sits above its industry’s benchmark range.

AMGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

20.22

AMGN
20.22
Max
15.46
Q3
7.32
Median
4.02
Q1
1.90
Min
-5.81

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

30.24

LLY
30.24
Max
15.46
Q3
7.32
Median
4.02
Q1
1.90
Min
-5.81
Loading chart…
Amgen (AMGN) vs. Eli Lilly (LLY): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Amgen (AMGN) and Eli Lilly (LLY)
MetricAMGNLLY
P/E Ratio (TTM)27.1738.61
P/S Ratio (TTM)6.2112.86
P/B Ratio (MRQ)20.2230.24
Free Cash Flow Yield (TTM)3.66%1.08%